Safety and efficacy of a classical swine fever subunit vaccine in pregnant sows and their offspring.
In the study three groups with five pregnant sows each were used. The animals were vaccinated twice, 2 weeks apart, in different stages of gestation, i.e. +/-4, +/-8 and +/-12 weeks after insemination and then 14 days later, respectively. From each group of sows three litters were randomly selected and vaccinated twice, 4 weeks apart, at 5 and 9, 7 and 11, and 9 and 13 weeks of life, respectively. Blood for serological investigations by virus neutralisation test and ELISA tests (for E(rns) antibodies and for E2 antibodies, separately) was taken before immunisation, at each vaccination and 2 weeks thereafter. Clinical observations shown that no local nor systemic reactions as well as no adverse effect on gestation occurred after vaccinations in any of the sows. Serological tests detected a low level of antibodies after the first vaccination and a typical booster effect after the second one. In piglets no adverse effect of the vaccination on the body weight gain was found. The presence of maternally derived antibodies (MDA) in non-vaccinated control piglets was observed up to the age of 5-13 weeks of life. The most evident immunological reaction was obtained in piglets vaccinated at the age of 5 or 7 weeks of life and revaccinated 4 weeks later. The CSFV-E2 subunit marker vaccine tested proved to be safe for pregnant sows and immunogenic for MDA positive piglets.